HNRNPH1 and chronic myelogenous leukemia, BCR-ABL1 positive: Due to the RBP nature of HNRNPH1, which has oncogene function and multiple transcriptional factor binding sites, HNRNPH1 could be a novel CML therapeutic target that has a huge potential clinical translation value.